Accretion Pharmaceuticals Peer Comparison
NSE: ACCPL
₹185.00
₹-1.00
(-0.54%)
As on 27-Oct-2026 11:08IST
Market cap
₹207 Cr
Revenue (TTM)
₹90 Cr
P/E Ratio
21.4
P/B Ratio
4
Div. Yield
0 %
Edit
| Accretion Pharmaceuticals | Wockhardt | Acutaas Chemicals | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
207 | 30,094 | 28,133 | 26,607 | 24,852 |
Revenue (₹ Cr) |
90 | 3,564 | 1,462 | 9,205 | 1,936 |
Net Profit (₹ Cr) |
9.67 | 414.00 | 387.35 | -371.81 | 288.22 |
Net Margin (%) |
10.76 | 11.23 | 26.01 | -3.93 | 14.79 |
RoE (%) |
28.72 | 8.38 | 25.18 | -3.85 | 29.77 |
Price to Earnings |
21.39 | 73.58 | 72.84 | -- | 86.23 |
Price-To-Book |
3.97 | 5.98 | 16.31 | 3.32 | 18.51 |
Income Statement (₹ Cr)
| Accretion Pharmaceuticals | Wockhardt | Acutaas Chemicals | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Operating Revenue
|
89.63 | 3,373.00 | 1,339.37 | 8,869.08 | 1,753.96 |
|
Total Income
|
89.82 | 3,510.00 | 1,380.95 | 9,111.51 | 1,762.66 |
|
Total Expenditure
|
74.65 | 2,747.00 | 858.97 | 7,976.59 | 1,354.69 |
|
EBITDA
|
14.97 | 626.00 | 480.40 | 892.49 | 399.26 |
|
Depreciation
|
1.21 | 227.00 | 35.99 | 831.24 | 45.26 |
|
EBIT
|
13.76 | 399.00 | 444.41 | 61.25 | 354.00 |
|
Interest
|
0.87 | 213.00 | 3.27 | 340.80 | 42.17 |
|
Other Income
|
0.19 | 137.00 | 41.59 | 242.43 | 8.70 |
|
Exceptional Items
|
-- | -85.00 | -- | -196.14 | -- |
|
Profit before Tax
|
13.08 | 238.00 | 482.73 | -176.06 | 320.53 |
|
Provision for Tax
|
3.42 | 39.00 | 126.36 | 149.88 | 73.80 |
|
Profit after Tax
|
9.67 | 199.00 | 356.37 | -325.94 | 246.74 |
Liabilities (₹ Cr)
| Accretion Pharmaceuticals | Wockhardt | Acutaas Chemicals | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
54.71 | 4,940.00 | 1,653.56 | 8,162.62 | 1,288.82 |
|
Minority Interest
|
-- | 341.00 | 57.19 | -- | 0.00 |
|
Non-Current Liabilities
|
1.13 | 1,235.00 | 42.40 | 4,529.41 | 189.02 |
|
Current Liabilities
|
20.84 | 1,622.00 | 230.81 | 4,874.74 | 835.87 |
|
Total Liabilities
|
76.68 | 8,578.00 | 1,983.96 | 17,723.32 | 2,326.71 |
Assets (₹ Cr)
| Accretion Pharmaceuticals | Wockhardt | Acutaas Chemicals | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
13.72 | 5,441.00 | 1,102.69 | 10,258.66 | 631.90 |
|
Current Assets
|
60.40 | 2,606.00 | 881.27 | 7,308.11 | 1,681.81 |
|
Total Assets
|
76.68 | 8,578.00 | 1,983.96 | 17,723.32 | 2,326.71 |
|
Total Debt*
|
12.32 | 2,125.00 | 26.49 | 5,495.48 | 259.37 |
|
Net Current Assets
|
39.56 | 984.00 | 650.46 | 2,433.37 | 845.94 |
|
Contingent Liabilities
|
-- | 768.26 | 17.25 | 95.72 | 19.09 |
Cashflow (₹ Cr)
| Accretion Pharmaceuticals | Wockhardt | Acutaas Chemicals | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-14.53 | 390.00 | 292.17 | 1,652.60 | 205.05 |
|
Cash Flow from Investing Activities
|
-8.53 | -241.00 | -265.94 | -826.03 | -409.72 |
|
Cash from Financing Activities
|
27.04 | -54.00 | 4.10 | -38.98 | 283.07 |
|
Net Cash Inflow / Outflow
|
3.97 | 95.00 | 30.33 | 787.59 | 78.39 |
Ratios
Profitability Ratios
| Accretion Pharmaceuticals | Wockhardt | Acutaas Chemicals | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
ROCE (%)
|
29.77 | 6.79 | 32.42 | 1.24 | 29.22 |
|
ROE (%)
|
28.72 | 4.29 | 24.08 | -4.04 | 27.84 |
|
ROA (%)
|
16.59 | 2.53 | 20.17 | -1.98 | 13.11 |
|
EBIT Margin (%)
|
16.92 | 22.62 | 38.97 | 12.80 | 23.26 |
|
Net Margin (%)
|
10.76 | 5.67 | 25.81 | -3.58 | 14.00 |
|
Cash Profit Margin (%)
|
12.14 | 10.98 | 29.29 | 4.80 | 7.71 |
Growth Ratios
| Accretion Pharmaceuticals | Wockhardt | Acutaas Chemicals | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
56.21 | 11.99 | 33.02 | -3.08 | 36.57 |
|
EBIT Growth (%)
|
26.62 | 67.69 | 109.63 | -28.15 | 52.29 |
|
Net Profit Growth (%)
|
42.31 | 449.12 | 122.15 | -457.66 | 83.64 |
|
EPS Growth (%)
|
4.59 | 553.20 | 348.92 | -456.91 | 71.44 |
|
Book Value Growth (%)
|
243.37 | 13.47 | 26.03 | 0.33 | 144.31 |
Valuation Ratios
| Accretion Pharmaceuticals | Wockhardt | Acutaas Chemicals | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Price / Earnings
|
7.31 | 89.54 | 58.79 | 0.00 | 51.69 |
|
Price / Book Value
|
1.35 | 3.87 | 12.69 | 2.24 | 10.14 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.10 | 0.00 | 0.19 |
|
EV/EBITDA
|
5.21 | 27.45 | 39.75 | 19.72 | 31.05 |
|
Market Cap (₹ Cr)
|
70.64 | 19,071.62 | 20,944.75 | 18,108.89 | 12,753.19 |
Solvency Ratios
| Accretion Pharmaceuticals | Wockhardt | Acutaas Chemicals | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.24 | 0.43 | 0.02 | 0.68 | 0.21 |
|
Short term debt to equity ratio
|
0.16 | 0.09 | 0.02 | 0.09 | 0.05 |
|
Current Ratio
|
2.90 | 1.61 | 3.82 | 1.50 | 2.01 |
|
Quick Ratio
|
1.54 | 1.06 | 2.82 | 0.87 | 1.14 |
|
Interest Coverage
|
16.03 | 2.12 | 148.71 | 0.48 | 8.60 |
Operating Efficiency Ratios
| Accretion Pharmaceuticals | Wockhardt | Acutaas Chemicals | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
24.99 | 17.43 | 27.07 | 24.33 | 29.00 |
|
Asset Turnover
|
1.54 | 0.49 | 0.76 | 0.64 | 2.01 |
|
Receivable days
|
69.36 | 58.75 | 88.98 | 78.20 | 40.13 |
|
Inventory Days
|
99.74 | 75.82 | 56.04 | 93.30 | 60.29 |
|
Payable days
|
37.40 | 186.21 | 99.95 | 226.14 | 232.47 |
|
Cash Conversion Cycle
|
131.70 | -51.64 | 45.07 | -54.64 | -132.04 |
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
